HeartBeam (NASDAQ: BEAT), a medical technology company focused on cardiac care, has announced its participation as a contributing partner in the launch of EXIT-CVD, a European cardiovascular research initiative co-funded by the European Union Innovative Health Initiative and industry partners. The consortium, led by University Medical Center Groningen and Royal Philips, brings together 42 organizations across 17 countries to conduct 22 clinical studies involving more than 14,000 patients, with a total budget of 27.6 million euros. For investors, this involvement signals a major validation of HeartBeam's technology and a potential catalyst for future growth.
HeartBeam will lead the HEART-CHECK study, which will evaluate its portable electrocardiogram (ECG) system for early detection and triage of cardiac events in high-risk patients recently discharged following acute coronary syndrome. The study will assess both the system's clinical performance and its integration into real-world care pathways. This is important because acute coronary syndrome patients are at high risk of recurrent events after discharge, and better monitoring could lead to earlier intervention and improved outcomes.
The HeartBeam System recently received U.S. Food and Drug Administration Breakthrough Device Designation for at-home heart attack assessment, an application that remains investigational. The system is designed to be cable-free and capable of collecting ECG signals in 3D from three non-coplanar directions, synthesizing them into a 12-lead ECG. This technology could enable patients to monitor their heart health outside of medical facilities, potentially reducing hospital readmissions and healthcare costs. In December 2024, the company received FDA clearance for arrhythmia assessment, and in December 2025, it received clearance for its 12-lead ECG synthesis software. HeartBeam holds over 20 issued patents related to technology enablement. For details on the cleared indications, refer to https://www.heartbeam.com/indications.
The EXIT-CVD consortium's broad scope and substantial funding underscore the growing emphasis on innovative cardiovascular solutions. HeartBeam's role in leading a key study within this initiative could accelerate the adoption of its technology in Europe and beyond, opening new market opportunities. As the company continues to develop its platform, successful outcomes from the HEART-CHECK study may support regulatory approvals and commercial expansion.
For ongoing updates on HeartBeam, visit the company's newsroom at https://ibn.fm/BEAT. The full press release can be accessed at https://ibn.fm/52Qtj. InvestorWire, a specialized communications platform, is powered by IBN, which offers solutions such as editorial syndication to 5,000+ outlets and social media distribution to help companies reach a wide audience. For more information on InvestorWire's services, including press release enhancement, visit InvestorWire. Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer.
